Article Commentary: Beyond the Direct Costs of Hepatitis C Treatment: The Balance between Costs and Ethics

Zaltron S. , Spinetti A. , Biasi L. , Baiguera C. , Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis 2012; 12 Suppl 2: S2.

Tamori A. , Enomoto M. , Kawada N. Recent advances in antiviral therapy for chronic hepatitis C. Mediators Inflamm 2016; 2016: 6841628.

Loy V. , Benyashvili T. , Adams W. , Pavkov D. , O'Mahoney M. , Cotler S.J. The time and cost investment required to obtain and initiate direct acting antiviral therapy. Antivir Ther 2016; doi:10.3851/IMP3068.

Deuffic-Burban S. , Obach D. , Canva V. Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case. J Viral Hepat 2016; doi:10.1111/jvh.12546.

Gray E. , O'Leary A. , Kieran J.A. Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection. J Viral Hepat 2016; 23: 677–686.

Maan R. , Zaim R. , van der Meer A.J. Real-world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis. J Gastroenterol Hepatol 2016; doi:10.1111/jgh.13373.

Mueller S. , Millonig G. , Seitz H.K. Alcoholic liver disease and hepatitis C: frequent underestimated combination. World J Gastroenterol 2009; 15: 3462–3471.

Sebhatu P. , Martin M.T. Genotype 1 hepatitis C virus and the pharmacist's role in treatment. Am J Health Syst Pharm 2016; 73: 764–774.

CDC. CDC's testing recommendations for hepatitis C virus infection. (Accessed 31 May 2015.) Available from http://www.cdc.gov/hepatitis/populations/1945-1965.htm.

Woode M.E. , Abu-Zaineh M. , Perriëns J. Potential market size and impact of hepatitis C treatment in low- and middle-income countries. J Viral Hepat 2016; 23: 522–534.

Kapczynski A. , Kesselheim A.S. Government patent use. A legal approach to reducing drug spending. Health Aff (Millwood) 2016; 35: 791–797.